Otelixizumab

Otelixizumab (ChAglyCD3) is an anti-human CD3 monoclonal antibody and can be used for the research of type 1 diabetes[1].

Product Specifications

CAS Number

[881191-44-2]

Product Name Alternative

ChAglyCD3; TRX 4

UNSPSC

12352203

Target

CD3

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/otelixizumab.html

Purity

99.64

Solubility

10 mM in DMSO

Smiles

[Otelixizumab]

Molecular Weight

(144.58 kDa)

References & Citations

[1]Kuhn C, et al. Human CD3 transgenic mice: preclinical testing of antibodies promoting immune tolerance. Sci Transl Med. 2011 Feb 2;3 (68) :68ra10.|[2]Guglielmi C, et al. Efficacy and safety of otelixizumab use in new-onset type 1 diabetes mellitus. Expert Opin Biol Ther. 2016 Jun;16 (6) :841-6.